• eTheRNA
  • Combining forces to bring innovative mRNA immunotherapies to the patients


Partnering is a key component of our corporate strategy. eTheRNA is open to exploring innovative ideas – at all stages of development.

eTheRNA focuses on maximizing the value of its proprietary TriMix technology via three routes:

  1. Technology Partnering: eTheRNA intends to build high-value strategic collaborations for exploring the benefits of the TriMix technology in various disease areas
  2. Product Partnering: eTheRNA seeks collaborative partnerships with pharma companies that enable us to develop - and ultimately also to commercialize - differentiated TriMix-based immunotherapies on either a risk-sharing or out-licensing basis
  3. mRNA Production Partnerning: eTheRNA is certifying to build a brand new mRNA production facilities with sufficient capacity to supply mRNA-constructs for its proper develpment plans as well as to cater for the needs of third parties